Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Geesje Hissink"'
Autor:
Annette Bakker, Angela M. Kaindl, D. Gareth Evans, Marco Nievo, Charlotte Carton, Cornelia Potratz, Rianne Oostenbrink, Edwin van de Ketterij, Britt A.E. Dhaenens, Rosalie E. Ferner, Guenter Heimann, Geesje Hissink, Eric Legius
Publikováno v:
European Journal of Medical Genetics, 64(9):104281. Elsevier Masson
Dhaenens, B A E, Ferner, R E, Evans, D G, Heimann, G, Potratz, C, van de Ketterij, E, Kaindl, A M, Hissink, G, Carton, C, Bakker, A, Nievo, M, Legius, E & Oostenbrink, R 2021, ' Lessons learned from drug trials in neurofibromatosis: A systematic review ', European journal of medical genetics, vol. 64, no. 9, 104281 . https://doi.org/10.1016/j.ejmg.2021.104281
Dhaenens, B A E, Ferner, R E, Evans, D G, Heimann, G, Potratz, C, van de Ketterij, E, Kaindl, A M, Hissink, G, Carton, C, Bakker, A, Nievo, M, Legius, E & Oostenbrink, R 2021, ' Lessons learned from drug trials in neurofibromatosis: A systematic review ', European journal of medical genetics, vol. 64, no. 9, 104281 . https://doi.org/10.1016/j.ejmg.2021.104281
Neurofibromatosis (NF) is the umbrella term for neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SWN). EU-PEARL aims to create a framework for platform trials in NF. The aim of this systematic review is to create an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024de6bb981c5bfed83b0f3675f3edf4
https://doi.org/10.1016/j.ejmg.2021.104281
https://doi.org/10.1016/j.ejmg.2021.104281
